Treatment of cancer

Global Liver Cancer Therapeutics Market By Cancer Type, By Therapy, By Equipment, By Age, By Factors, By Route of Administration, By Region, Forecast & Opportunities, 2025

Wednesday, July 1, 2020 - 5:30pm

Global liver cancer therapeutics market is expected to grow at a brisk CAGR during the forecast period.

Key Points: 
  • Global liver cancer therapeutics market is expected to grow at a brisk CAGR during the forecast period.
  • According to World Cancer Research Fund, liver cancer is the sixth most common cancer across the globe.Therefore, scientists are working on developing more innovative drugs and therapies for liver cancer treatment.
  • Expensive treatments as well as high cost in research and development might hamper the further growth of liver cancer therapeutics market.
  • The intravenous segment is anticipated to dominate the global liver cancer therapeutics market during the forecast period as it is most preferred route of administration for chemotherapy.

Why Biomarkers for Cancer Drug Development are Becoming Increasingly Imperative

Tuesday, June 30, 2020 - 1:45pm

Biomarker-based tests have been in existence for over a few decades but their relevance to drug development and diagnostics applications in particular has gained momentum recently.

Key Points: 
  • Biomarker-based tests have been in existence for over a few decades but their relevance to drug development and diagnostics applications in particular has gained momentum recently.
  • NIH said: "Cancer is an uncontrolled growth of a cell due to failure in the cell growth signaling system.
  • Cure of cancer is done only by the complete removal of cancerous cells from the body, the process may sound simple but its implementation is almost impossible.
  • As early detection is half victory in any disease, especially cancer, this kind of research will be advantageous in the field of cancer treatment."

Why Biomarkers for Cancer Drug Development are Becoming Increasingly Imperative

Tuesday, June 30, 2020 - 1:45pm

Biomarker-based tests have been in existence for over a few decades but their relevance to drug development and diagnostics applications in particular has gained momentum recently.

Key Points: 
  • Biomarker-based tests have been in existence for over a few decades but their relevance to drug development and diagnostics applications in particular has gained momentum recently.
  • NIH said: "Cancer is an uncontrolled growth of a cell due to failure in the cell growth signaling system.
  • Cure of cancer is done only by the complete removal of cancerous cells from the body, the process may sound simple but its implementation is almost impossible.
  • As early detection is half victory in any disease, especially cancer, this kind of research will be advantageous in the field of cancer treatment."

The EndBrainCancer Initiative Announces Partnership with GT Medical Technologies, Creators of GammaTile Therapy for Patients with Brain Tumors

Tuesday, June 30, 2020 - 11:26am

SEATTLE, June 30, 2020 /PRNewswire/ --The EndBrainCancer Initiative (EBCI) announced today that GT Medical Technologies , manufacturers of GammaTile Therapy for Brain Cancer Patients, has joined EBCI's roster of corporate partners.

Key Points: 
  • SEATTLE, June 30, 2020 /PRNewswire/ --The EndBrainCancer Initiative (EBCI) announced today that GT Medical Technologies , manufacturers of GammaTile Therapy for Brain Cancer Patients, has joined EBCI's roster of corporate partners.
  • According to the EndBrainCancer Initiative, GT Medical Technologies is dedicated to improving the lives of patients with brain tumors through a promising new intervention in the treatment of brain cancer, GammaTile Therapy.
  • GammaTile Therapy is an FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) for patients with newly diagnosed malignant and recurrent brain tumors including primary and metastatic tumors.
  • According to the EndBrainCancer Initiative, the partnership with will result in:
    Education, Awareness & Outreach about GammaTile Therapy to a National audience of patients with brain tumors, their caregivers, medical practitioners, industry, and the general public with a total annual reach of over 18,000,000.

Global Genomic Cancer Panel and Profiling Markets (2020 to 2024) - Featuring Agena Bioscience, Agilent & Almac Diagnostics Among Others - ResearchAndMarkets.com

Monday, June 29, 2020 - 3:53pm

The "Genomic Cancer Panel and Profiling Markets by Cancer and Germline/Somatic Type with Screening Potential Market Size, Customized Forecasting/Analysis, and Executive and Consultant Guides 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genomic Cancer Panel and Profiling Markets by Cancer and Germline/Somatic Type with Screening Potential Market Size, Customized Forecasting/Analysis, and Executive and Consultant Guides 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • Cancer Gene Panels and Genomic Profiling are quickly changing the diagnosis and treatment of cancers.
  • The market is moving out of a specialized niche and going mainstream as Oncologists begin routinely using the information on the hundreds of genes related to cancer.
  • The market is exploding as physicians use all the information they can get in the battle against cancer.

Nucleix Announces Publication of Data on Methylation-Based Assay for Detecting High-Risk Non-Muscle Invasive Bladder Cancer in Journal of Clinical Pathology

Monday, June 29, 2020 - 1:00pm

Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced the publication of an independent study in the Journal of Clinical Pathology evaluating the companys urine-based Bladder EpiCheck in patients diagnosed with high-grade non-muscle invasive bladder cancer (NMIBC).

Key Points: 
  • Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced the publication of an independent study in the Journal of Clinical Pathology evaluating the companys urine-based Bladder EpiCheck in patients diagnosed with high-grade non-muscle invasive bladder cancer (NMIBC).
  • The findings support the use of the Bladder EpiCheck methylation biomarkers to detect bladder cancer recurrence in NMIBC patient populations that have undergone instillations.
  • Bladder EpiCheck is intended for use as a noninvasive method for monitoring of tumor recurrence in conjunction with cystoscopy in patients previously diagnosed with bladder cancer.
  • We are building an EpiCheck franchise, beginning with our Bladder EpiCheck testing kit marketed in Europe for bladder cancer recurrence.

Cancer Immunotherapy Gets Boost from Newly Engineered Nanoparticles

Thursday, June 25, 2020 - 3:30pm

It is anticipated that the new therapies may transition to a lead cancer treatment in the near future.

Key Points: 
  • It is anticipated that the new therapies may transition to a lead cancer treatment in the near future.
  • The brain trust of MIT engineers has managed to come up with a way to boost the effectiveness of one type of cancer immunotherapy.
  • Implementing a multifaceted treatment in this way could allow cancer immunotherapy to benefit a greater percentage of patients, the researchers say.
  • After creating their nanoparticles, the researchers from MIT reported testing them in several different mouse models of cancer.

Cancer Immunotherapy Gets Boost from Newly Engineered Nanoparticles

Thursday, June 25, 2020 - 3:30pm

It is anticipated that the new therapies may transition to a lead cancer treatment in the near future.

Key Points: 
  • It is anticipated that the new therapies may transition to a lead cancer treatment in the near future.
  • The brain trust of MIT engineers has managed to come up with a way to boost the effectiveness of one type of cancer immunotherapy.
  • Implementing a multifaceted treatment in this way could allow cancer immunotherapy to benefit a greater percentage of patients, the researchers say.
  • After creating their nanoparticles, the researchers from MIT reported testing them in several different mouse models of cancer.

Advancements in Breast Cancer Research & Clinical Studies Producing Optimism for New Treatments

Thursday, June 25, 2020 - 1:45pm

The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer.

Key Points: 
  • The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer.
  • In a new research study, Persistence Market Research estimates the globaltriple-negative breast cancer treatment marketrevenue to crossUS$ 720 Mn by 2026from an estimated valuation of just underUS$ 505 Mn in 2018.
  • Companies in the global triple-negative breast cancer treatment market are conducting clinical trials for combination therapies by collaborating with other players in the market.
  • Verzenio is approved to treat advanced breast cancer and is not approved for an early stage breast cancer indication.

Advancements in Breast Cancer Research & Clinical Studies Producing Optimism for New Treatments

Thursday, June 25, 2020 - 1:45pm

The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer.

Key Points: 
  • The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer.
  • In a new research study, Persistence Market Research estimates the globaltriple-negative breast cancer treatment marketrevenue to crossUS$ 720 Mn by 2026from an estimated valuation of just underUS$ 505 Mn in 2018.
  • Companies in the global triple-negative breast cancer treatment market are conducting clinical trials for combination therapies by collaborating with other players in the market.
  • Verzenio is approved to treat advanced breast cancer and is not approved for an early stage breast cancer indication.